PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of canjcardiolThe Canadian Journal of Cardiology HomepageSubscription pageSubmissions Pagewww.pulsus.comThe Canadian Journal of Cardiology
 
Can J Cardiol. 2009 May; 25(5): 309–314.
PMCID: PMC2707167

Language: English | French

Hypertension in dialysis and kidney transplant patients

GV Ramesh Prasad, MD FRCPC,1 Marcel Ruzicka, MD PhD FRCPC,2 Kevin D Burns, MD FRCPC,3 Sheldon W Tobe, MD FRCPC,4 and Marcel Lebel, MD FRCPC FASN FAHA5

Abstract

For the first time, the Canadian Hypertension Education Program has studied the evidence supporting blood pressure control in people requiring renal replacement therapy for end-stage kidney disease, including those on dialysis and with renal transplants. According to the Canadian Organ Replacement Registry’s 2008 annual report, there were an estimated 33,832 people with end-stage renal disease in Canada at the end of 2006, an increase of 69.7% since 1997. Of these, 20,465 were on dialysis and 13,367 were living with a functioning kidney transplant. Thus, it is becoming more likely that primary care practitioners will be helping to care for these complex patients. With the lack of large controlled clinical trials, the consensus recommendation based on interpretation of the existing literature is that blood pressure should be lowered to below 140/90 mmHg in hypertensive patients on renal replacement therapy and to below 130/80 mmHg for renal transplant patients with diabetes or chronic kidney disease.

Keywords: Antihypertensive drugs, Calcineurin inhibitors, Corticosteroids, Hemodialysis, Immunosuppression, Kidney transplantation, Peritoneal dialysis, Renal artery stenosis

Résumé

Pour la première fois, le Programme éducatif canadien sur l’hypertension a étudié les données probantes étayant le contrôle de la tension artérielle chez les personnes qui ont besoin d’une transplantation rénale en raison d’une insuffisance rénale chronique au stade ultime, y compris ceux qui sont en dialyse ou sont greffés du rein. D’après le rapport annuel 2008 du Registre canadien du remplacement d’organes, on estimait que 33 832 personnes étaient atteintes d’insuffisance rénale au stade ultime au Canada à la fin de 2006, une augmentation de 69,7 % depuis 1997. De ce nombre, 20 465 étaient en dialyse, et 13 367 vivaient avec une greffe d’organe fonctionnelle. Ainsi, il devient plus probable que les praticiens de premier recours contribueront aux soins de ces patients complexes. Étant donné l’absence de grand essai clinique contrôlé, la recommandation consensuelle fondée sur l’interprétation des publications existantes indique qu’il faudrait abaisser la tension artérielle à moins de 140/90 mmHg chez les patients hypertendus en voie de subir une transplantation rénale et à moins de 130/80 mmHg chez les patients greffés du rein atteints de diabète ou d’insuffisance rénale chronique.

Reports from the Canadian Organ Replacement Register (1) show that cardiovascular diseases remain the leading cause of death among patients on dialysis therapy and after renal transplantation. Hypertension is observed in approximately 80% to 90% of patients by the time chronic kidney disease (CKD) progresses to end-stage renal failure (stage 5), thereby favouring the development of left ventricular hypertrophy (LVH) (2). In addition, dialysis and transplantation patients often do not show the normal reduction in nocturnal blood pressures (BPs). This phenomenon increases the BP load and favours LVH, which is an independent risk predictor of cardiovascular complications in dialysis patients (3).

The present overview will not only underscore the importance of hypertension as a cardiovascular risk factor for dialysis and kidney transplant patients, but will also review mechanisms, diagnostic methods and management of hypertension.

HYPERTENSION IN DIALYSIS PATIENTS

Physiopathology

The most common pattern of BP in dialysis patients is systolic hypertension associated with a wide pulse pressure due to atherosclerotic arterial stiffness (4). The main pathogenic mechanisms of hypertension in dialysis patients are summarized in Table 1. Extracellular fluid overload is the most common feature in hypertensive dialysis patients. Indeed, insufficient volume removal is often the major factor responsible for dialysis-refractory hypertension (5). In many patients, there is also an abnormal relationship between extracellular fluid volume and the renin-angiotensin system (RAS) (6) – the circulating renin concentration is abnormally high for the exchangeable sodium levels. In addition, volume fluctuations such as plasma volume contraction during a dialysis session or interdialytic fluid overload result in activation of the sympathetic nervous system (7). Several additional factors also contribute to increase sympathetic outflow in this population including renal ischemia, increased activity of the RAS, nocturnal hypoxemia and prevalent comorbidities such as chronic heart failure.

TABLE 1
Mechanisms of hypertension in dialysis patients

Imbalance in endothelium-derived factors has also been reported in end-stage renal disease (8). In the 5/6 nephrectomy animal model, the vascular production of endothelin (ET)-1 is increased (9) and the expression of ETB, an ET-1 clearance receptor, is reduced (10). The pressor effect of ET-1 is enhanced by the concomitant decrease of potent vasodilators such as prostacyclin and nitric oxide (NO). The production of NO by the blood vessel endothelium is inhibited by the accumulation (six- to 10-fold) of asymmetric dimethylarginine, which inhibits NO synthesis in CKD (11).

Erythropoietin (EPO) replacement therapy in anemic dialysis patients may also aggravate pre-existing hypertension (12). The precise mechanism underlying the development of hypertension following EPO therapy is still unclear. The pressor effect of EPO cannot only be accounted for by an increase in hematocrit and blood viscosity (1214). Other potential mechanisms include an inappropriate increase in peripheral resistance (12), enhanced tissue renin activity (15) and an increase in angiotensin II receptor expression (16). Recent evidence also suggests that EPO accentuates a pre-existing endothelial dysfunction. Blood vessel endothelial cells express EPO receptors (17) and these cells, when stimulated by EPO, release ET-1 (18). In vivo studies also demonstrate that EPO treatment can modulate ET-1 messenger RNA expression in the renal cortex of uremic rats (8), and can increase vascular and renal cortex ET-1 concentration in uremic rats (19,20), a phenomenon that can contribute to EPO-induced hypertension. Consistent with this, selective ETA receptor blockade prevents the worsening of hypertension in EPO-treated uremic rats (21,22). A recent study (23) showed that EPO exerts a pleiotropic effect on the vascular endothelial ET-1/ETB receptor system.

Secondary hyperparathyroidism can also contribute to hypertension in end-stage renal disease by favouring entry of calcium into vascular smooth muscle cells (24). Reports that showed that the treatment of hyperparathyroidism by vitamin D administration or parathyroidectomy in dialysis patients result in improved BP support this hypothesis (25).

Sleep disturbances are more frequent in end-stage renal disease than in the general population (26) and may contribute to hypertension in dialysis patients. Therefore, sleep apnea should be investigated in dialysis patients with resistant hypertension without other causes, mainly in those with compatible symptoms.

When and how to monitor BP?

Variation of blood fluid volumes in dialysis patients before, during and after hemodialysis cause marked fluctuations in BP. It remains unclear which BP recording (immediately predialysis or postdialysis) is more predictive of patient outcomes. Indeed, the predialysis systolic BP may overvalue and the postdialysis systolic BP may underrate the mean interdialytic BPs by 10/7 mmHg (27). Agarwal et al (28) recently demonstrated that the median BP, including predialysis, intradialytic and postdialysis BPs, provides improved sensitivity and specificity in diagnosing hypertension in hemodialysis patients. The role of 24 h ambulatory BP monitoring (ABPM) and home BP self-monitoring in hemodialysis patients is still being evaluated. An ABPM value seems reproducible and may be useful in evaluating systolic BP load, which is a key factor in the development of LVH (29). Approximately 70% of hemodialysis patients lack their circadian BP variation (ie, nondippers) and develop nocturnal hypertension (12), a phenomenon that contributes to increasing BP load. Interestingly, a significant correlation was observed between traditional supine mean BP readings after dialysis and 24 h ABPM interdialysis measurements (30). Similarly, Mitra et al (31) reported that the best representation of interdialytic ABPM values was the 20 min sitting postdialysis measure. Home BP self-monitoring also provides valuable information. Agarwal (32) observed a good correlation between average systolic and diastolic ABPM values and respective home BP self-monitoring readings.

What is the target BP in dialysis patients with hypertension?

Observational studies in hemodialysis patients have yielded paradoxical results on the relationship between BP level and cardiovascular morbidity and mortality risk. These relationships may be different from those observed in general populations. Low BP appears to be associated with higher mortality during the early years of dialysis, whereas high BP is associated with mortality in longer-term follow-up (33,34). Low predialytic BP in the dialysis population is likely not the result of overtreatment but may be a marker of congestive heart failure. Furthermore, other observational studies in hemodialysis cohorts showed a reverse epidemiology phenomenon, with the highest mortality rate in patient groups with lower BPs (35,36). Similar results were reported in a retrospective analysis performed in peritoneal dialysis patients (37). In the absence of randomized controlled trials (RCTs), the Canadian Society of Nephrology guidelines (38) and the Canadian Hypertension Education Program (CHEP) (see the coming 2009 report) recommend a predialysis BP target of less than 140/90 mmHg.

Therapy

Nonpharmacological treatment of hypertensive dialysis patients:

Control of sodium and water balance with achievement of dry body weight with adequate dialysis prescription can either improve or even normalize BP in dialysis patients (39,40). An interdialytic weight gain as small as 2.5 kg is associated with a significant increase in BP (41). It is noteworthy that after achievement of dry weight, there may be a long period of time before BP improves, also denoted as the ‘lag phenomenon’ (42). To diminish large interdialytic weight gains, dialysis patients should be on a salt-restricted diet, which also reduces thirst, an important aspect of patient adherence. If the dialysate sodium concentration during hemodialysis is to be ramped to prevent intradialytic hypotension and cramping, normalization of the sodium level before the end of dialysis will also attenuate postdialysis thirst and interdialytic weight gain, and may result in a reduction of antihypertensive agents to control BP (43,44). The dialysis regimen is also an important factor in the control of BP in dialysis patients. Long duration hemodialysis treatments (three 8 h sessions/week) are associated with better BP control and reduction of cardiovascular complications (39). Nocturnal dialysis treatment (six 8 h sessions/week) increases arterial baroreflex sensitivity and normalizes BP (45,46). Long nocturnal home hemodialysis can also improve sleep apnea (47).

Antihypertensive drugs:

The use of antihypertensive drugs is indicated for patients in whom hypertension remains despite seemingly proper volume control. High BP in dialysis patients can usually be controlled with the use of the same antihypertensive drugs used in nondialysis patients with CKD (48). The selection of antihypertensive agents is often dictated by the presence of coexisting diseases. An overly rapid intensification of the antihypertensive medication may result in dialysis-induced hypotension and inability to achieve dry weight.

Angiotensin-converting enzyme inhibitors:

Angiotensin-converting enzyme (ACE) inhibitors are effective and usually well tolerated in dialysis patients. They can reverse LVH (49,50) and can reduce mortality (51). Dose adjustment is necessary for ACE inhibitors with renal elimination. They can also trigger anaphylactoid reactions in patients dialysed with AN69 membranes (52).

Angiotensin II receptor blockers:

Although there is limited experience with angiotensin II receptor blockers (ARBs) in dialysis patients, they also seem well tolerated in this patient population. A recent open-label, randomized trial in 366 patients showed that an ARB may be effective in reducing nonfatal cardiovascular events in patients on long-term hemodialysis (53). Dose adjustment of ARBs in patients on hemodialysis is not necessary.

Calcium channel blockers:

Calcium channel blockers (CCBs) are effective and well tolerated in dialysis patients, even in those who are volume expanded (54). Among dialysis patients with pre-existing cardiovascular disease, dihydropyridine CCBs and nondihydropyridine CCBs were associated with a significant reduction in cardiovascular mortality (55). A recent study (56) showed that amlodipine safely reduced systolic BP in a cohort of hemodialysis patients. Because of the negative chronotropic action of nondihydropyridine CCBs, combination with beta-blockers should be avoided.

Other antihypertensive drugs such as beta-blockers, alpha-1-adrenergic receptor blockers and centrally acting agents can be used in an association regimen to achieve BP targets. Beta-blockers are indicated in patients with coronary artery disease. In hemodialysis patients with dilated cardiomyopathy, a randomized trial (57) demonstrated that the vasodilating beta-blocker, carvedilol, significantly reduced morbidity and mortality over two years. Liposoluble beta-blockers (nadolol and atenolol) are cleared by the kidney and dose adjustment is necessary to prevent excessive bradycardia.

It is noteworthy that if volume overload is not properly corrected with dialysis, hypertension will remain despite the use of antihypertensive drugs.

Prospective RCTs are needed to determine the effect of antihypertensive drugs on cardiovascular outcomes in dialysis patients.

HYPERTENSION AFTER RENAL TRANSPLANTATION

The most common causes of kidney transplant failure are death with a functioning allograft and chronic allograft dysfunction (58,59). Cardiovascular disease is known to cause approximately 40% of deaths among renal transplant recipients and is its largest single cause (60). Thus, an understanding of the cardiovascular risk in renal transplant recipients is critical to the development of effective preventive and interventional strategies for this large population group. The epidemiology, diagnosis and management of postrenal transplant hypertension is reviewed in the following sections.

Prevalence, importance and etiology

Hypertension is widely prevalent following kidney transplantation (61), with rates of 67% to 90% since the introduction of cyclosporine in 1983 (62), compared with rates of 45% to 55% before then (61).

Post-transplant hypertension is a risk factor for cardiovascular disease (63) and chronic renal allograft dysfunction (64,65). There is a strong positive association between levels of BP control and risk for subsequent renal allograft failure (66), even after adjustment for baseline renal function (67). For each 10 mmHg rise in systolic BP, the risk for allograft loss is increased by 12% to 15% (67,68). A systolic BP of greater than 140 mmHg is associated with diminished long-term allograft survival, regardless of whether antihypertensive agents are used (66). An elevated BP also predicts acute rejection (69). Thus, adequate control of BP is an important goal for transplant recipients.

The etiology of hypertension following renal transplant includes ongoing essential hypertension, the presence of diseased native kidneys, allograft dysfunction due to acute tubular necrosis, acute rejection or chronic dysfunction, recurrent and de novo glomerular disease in the allograft, transplant renal artery stenosis, and immunosuppressive medication including calcineurin inhibitors (CNIs; cyclosporine or tacrolimus) or corticosteroids (68). Persistent post-transplant hyperparathyroidism is also a cause, and hypertension can also be caused by the donor organ (70). The etiology in a given patient is usually multifactorial (Table 2).

TABLE 2
Causes of post-transplant hypertension

Both CNIs and steroids cause sodium retention and volume expansion, with associated low plasma renin levels (71). CNIs cause afferent arteriolar vasoconstriction by increasing sympathetic nervous system activity, intrarenal RAS activity and ET-1 synthesis and release; decreasing NO production and vasodilator prostaglandins; and increasine vasoconstrictor cytokines (7274).

Renal artery stenosis may manifest at any time, but is most common between three months and two years post-transplant (75). It has a frequency of 5% to 10%, is more common when the right kidney is used, and may be caused by rejection of the donor artery, clamp or perfusion pump cannulation injury, vessel size disproportion, inflammation from the suture material used, or extension of external iliac artery atherosclerosis (76,77).

Diagnosis and treatment targets

Diagnostic tools and methods used for renal transplant recipients are similar to those for the general population in the absence of evidence for a different approach. Diagnosing hypertension in the post-transplant clinic is often straightforward, although renal transplant recipients do exhibit masked hypertension and a white coat effect (78). As in other forms of CKD, ABPM has been found to be a stronger predictor of renal function (79) and LVH (80) than office BP. ABPM is an excellent tool to diagnose masked hypertension and white coat hypertension, and to assess the diurnal pattern of BP. A nondipping pattern of nocturnal BP has been found to have a prevalence of up to 90% in renal transplant recipients (81). Because office BP would have misdiagnosed 15% to 37% of hypertensive renal transplant recipients as being normotensive, this suggests that the prevalence of masked hypertension is likely high in this population (82,83).

The CHEP guidelines should be followed in the initial investigation of hypertension in renal transplant recipients akin to the general hypertensive population. However, given the unique characteristics of this patient group, a broad differential diagnosis must be entertained and the relevant investigations ordered where appropriate. These are summarized in Table 3. In addition to ABPM, other investigations, where indicated, include monitoring trends in renal function to detect new-onset dysfunction from conditions such as acute rejection and recurrent or de novo glomerular disease, and detecting proteinuria, which is strongly associated with elevated BP (84). An allograft biopsy may be required to establish the diagnosis. High serum calcium and parathyroid hormone levels may indicate persistent post-transplant hyperparathyroidism. A high hemoglobin level may indicate post-transplant erythrocytosis, and a high CNI blood level may be a reflection of chronic overexposure. If BP reduction is unusually difficult, particularly when it is accompanied by renal function compromise, an ultrasound of the renal allograft with Doppler interrogation of the renal vessels may establish a diagnosis of renal artery stenosis. Angiography with carbon dioxide-containing contrast may be considered to avoid contrast-induced nephropathy.

TABLE 3
Management of post-transplant hypertension

The CHEP recommends that the treatment of hypertension in renal transplant recipients be the same as in other hypertensive patients. Unless specific comorbidities such as diabetes mellitus or CKD dictate specific targets (ie, less than 130/80 mmHg), a BP target of less than 140/90 mmHg is considered appropriate. In the absence of sufficient outcomes evidence, this recommendation is based on consensus opinion. European guidelines (85) provide a target of less than 130/85 mmHg for those without proteinuria and less than 125/75 mmHg for those with proteinuria, while American Society of Transplantation guidelines (63) prescribe a target of less than 140/90 mmHg. Although clinical trials are lacking, retrospective data demonstrated that achieving BP control was associated with improved allograft and patient survival (86). A decrease in nocturnal systolic BP was also associated with regression of LVH (87).

Management

Patients with renal transplants should also undergo nonpharmacological interventions including lifestyle modification and stress reduction therapy. Concurrent pharmacological intervention is advised if the BP is persistently above target and/or target organ damage is present (85). The BP-lowering effect of regular exercise and weight reduction, reducing salt and alcohol intake, and pursuing a less stressful lifestyle have not been systematically evaluated in the transplant population. Although CNIs cause salt retention and volume expansion, BP does not correlate with 24 h urine sodium excretion (84). Therapy for hyperlipidemia with statins may result in BP lowering (88).

Hypertension is very common in the immediate post-transplant period due to the use of higher doses of CNIs and steroids. As drug doses are lowered, the BP declines but is unlikely to reach the normotensive range. Some reports indicate that tacrolimus causes less hypertension than cyclosporine (89). In the Diabetes Incidence after Renal Transplantation: neoral C2 monitoring versus Tacrolimus (DIRECT) trial (90), both BP and the use of antihypertensive medication were not different between cyclosporine and tacrolimus at six months. The use of sirolimus instead of CNIs may result in better BP control (91), as demonstrated in the Rapamune Maintenance Regimen (RMR) trial (92). However, the Efficacy Limiting Toxicity Elimination-Symphony (ELITE-Symphony) study (93) of 1645 patients demonstrated no important difference in BP among four different immunosuppressive drug regimens. To date, steroid withdrawal has not been demonstrated to have a favourable impact on BP (94).

The use of antihypertensive agents is often dictated by comorbidities such as cardiovascular disease and proteinuria (63). Multiple agents are typically required. There are no studies to date evaluating long-term renal and cardiovascular outcomes among different BP-lowering drug classes. CCBs reverse CNI-induced afferent arteriolar vasoconstriction and are associated with higher glomerular filtration rates than ACE inhibitors (95) in the short term, likely due to increased renal blood flow. The use of CCBs is associated with earlier allograft function recovery and better long-term allograft function when used with cyclosporine (71). Nondihydropyridine CCBs interact with CNIs through the hepatic cytochrome P450 system, thereby raising CNI levels; consequently, careful CNI blood level monitoring is required. Despite this, diltiazem has been used safely with both cyclosporine and tacrolimus (96). Beta-blockers increase the risk of dysglycemia and dyslipidemia to which renal transplant recipients are already prone. Alpha-blockers are theoretically beneficial because they reduce peripheral resistance without decreasing renal plasma flow. A long-term study has demonstrated their efficacy in the transplant population (97). Loop diuretics are helpful in states of volume expansion, but may exacerbate the prerenal azotemia caused by CNIs.

The RAS antagonists in the transplant population have been studied and shown to be safe and efficacious when used over long periods (98). A small RCT comparing nifedipine to lisinopril (95) showed a lower glomerular filtration rate in the lisinopril group after two years. A renal protective effect on 10-year allograft survival rate with an ACE inhibitor or ARB was found in a retrospective cohort study of 2031 renal transplant patients (99). However, this finding was not confirmed in another registry-based analysis (100). Presently, an RCT comparing ramipril with placebo in renal transplant recipients with proteinuria with the change in BP as a secondary end point is ongoing (101). Regular monitoring of allograft function, extracellular fluid volume status, and serum potassium levels is advised whenever RAS antagonists are prescribed or their dose is adjusted.

Clinically significant transplant renal artery stenosis can be treated by percutaneous transluminal angioplasty or surgical bypass. Although initial results are good, long-term follow-up studies are sparse. Selection of appropriate patients remains difficult (102). There is an approximately 20% restenosis rate with angioplasty (103). Intra-arterial stenting can also be performed, particularly in the event of recurrent stenosis (104). In a small series of six patients with recurrent RAS who received metallic stents, no further recurrence was reported after three years (105). Surgical repair, usually reserved for those with proximal recipient arteriosclerotic disease, is associated with a 10% stenosis recurrence rate and 30% allograft loss rate (103,106). In rare cases of resistant hypertension, in which the etiology is thought to be of native renal origin (eg, ischemia), bilateral native nephrectomy should be considered (107,108).

REFERENCES

1. Canadian Organ Replacement Register, Canadian Institute for Health Information . Toronto: Canadian Institute for Health Information; 2008. Renal replacement therapy for end-stage renal disease and kidney transplantation; pp. 5–24. Annual Report.
2. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int. 1996;49:1379–85. [PubMed]
3. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 1996;11:1277–85. [PubMed]
4. Locatelli F, Covic A, Chazot C, Leunissen K, Luno J, Yaqoob M. Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant. 2004;19:1058–68. [PubMed]
5. Fishbane S, Natke E, Maesaka JK. Role of volume overload in dialysis-refractory hypertension. Am J Kidney Dis. 1996;28:257–61. [PubMed]
6. Schalekamp MA, Beevers DG, Briggs JD, et al. Hypertension in chronic renal failure. An abnormal relation between sodium and the renin-angiotensin system. Am J Med. 1973;55:379–90. [PubMed]
7. Converse RL, Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912–8. [PubMed]
8. Lariviere R, Lebel M. Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol. 2003;81:607–21. [PubMed]
9. Lariviere R, D’Amours M, Lebel M, Kingma I, Grose JH, Caron L. Increased immunoreactive endothelin-1 levels in blood vessels and glomeruli of rats with reduced renal mass. Kidney Blood Press Res. 1997;20:372–80. [PubMed]
10. D’Amours M, Lebel M, Larivière R. Increased ET-1 and reduced ETb receptor expression in uremic rats. Clin Exp Hypertens 2009. (In press)
11. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572–5. [PubMed]
12. Lebel M, Kingma I, Grose JH, Langlois S. Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients. J Am Soc Nephrol. 1998;9:97–104. [PubMed]
13. Kaupke CJ, Kim S, Vaziri ND. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol. 1994;4:1874–8. [PubMed]
14. Vaziri ND, Zhou XJ, Naqvi F, et al. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol. 1996;271:E113–22. [PubMed]
15. Eggena P, Willsey P, Jamgotchian N, et al. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol. 1991;261:E642–6. [PubMed]
16. Barrett JD, Zhang Z, Zhu JH, et al. Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells. J Hypertens. 1998;16:1749–57. [PubMed]
17. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A. 1994;91:3974–8. [PubMed]
18. Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int. 1996;50:1255–61. [PubMed]
19. Lebel M, Lacasse MS, Lariviere R, Kingma I, Grose JH. Plasma and blood vessel endothelin-1 concentrations in hypertensive uremic rats treated with erythropoietin. Clin Exp Hypertens. 1998;20:939–51. [PubMed]
20. Lebel M, Rodrigue ME, Agharazii M, Lariviere R. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. Am J Hypertens. 2006;19:1286–92. [PubMed]
21. Brochu E, Lacasse S, Lariviere R, Kingma I, Grose JH, Lebel M. Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol. 1999;10:1440–6. [PubMed]
22. Rodrigue ME, Moreau C, Lariviere R, Lebel M. Relationship between eicosanoids and endothelin-1 in the pathogenesis of erythropoietin-induced hypertension in uremic rats. J Cardiovasc Pharmacol. 2003;41:388–95. [PubMed]
23. Rodrigue ME, Brochu I, D’Orleans-Juste P, Lariviere R, Lebel M. Effect of erythropoietin on blood pressure and on the vascular endothelial ET-1/ETb receptor system. Am J Hypertens. 2008;21:639–43. [PubMed]
24. Massry SG, Iseki K, Campese VM. Serum calcium, parathyroid hormone, and blood pressure. Am J Nephrol. 1986;(6 Suppl 1):19–28. [PubMed]
25. Goldsmith DJ, Covic AA, Venning MC, Ackrill P. Blood pressure reduction after parathyroidectomy for secondary hyperparathyroidism: Further evidence implicating calcium homeostasis in blood pressure regulation. Am J Kidney Dis. 1996;27:819–25. [PubMed]
26. De Santo RM, Bartiromo M, Cesare MC, De Santo NG, Cirillo M. Sleeping disorders in patients with end-stage renal disease and chronic kidney disease. J Ren Nutr. 2006;16:224–8. [PubMed]
27. Luik AJ, Kooman JP, Leunissen KM. Hypertension in haemodialysis patients: Is it only hypervolaemia? Nephrol Dial Transplant. 1997;12:1557–60. [PubMed]
28. Agarwal R, Metiku T, Tegegne GG, et al. Diagnosing hypertension by intradialytic blood pressure recordings. Clin J Am Soc Nephrol. 2008;3:1364–72. [PubMed]
29. Conion PJ, Walshe JJ, Heinle SK, Minda S, Krucoff M, Schwab SJ. Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Nephrol. 1996;7:2658–63. [PubMed]
30. Lebel M, Kingma I, Grose JH, Langlois S. Effect of recombinant human erythropoietin therapy on ambulatory blood pressure in normotensive and in untreated borderline hypertensive hemodialysis patients. Am J Hypertens. 1995;8:545–51. [PubMed]
31. Mitra S, Chandna SM, Farrington K. What is hypertension in chronic haemodialysis? The role of interdialytic blood pressure monitoring. Nephrol Dial Transplant. 1999;14:2915–21. [PubMed]
32. Agarwal R. Role of home blood pressure monitoring in hemodialysis patients. Am J Kidney Dis. 1999;33:682–7. [PubMed]
33. Mazzuchi N, Carbonell E, Fernandez-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int. 2000;58:2147–54. [PubMed]
34. Stidley CA, Hunt WC, Tentori F, et al. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol. 2006;17:513–20. [PubMed]
35. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Greenland S, Kopple JD. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population. Hypertension. 2005;45:811–7. [PubMed]
36. Li Z, Lacson E, Jr, Lowrie EG, et al. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis. 2006;48:606–15. [PubMed]
37. Goldfarb-Rumyantzev AS, Baird BC, Leypoldt JK, Cheung AK. The association between BP and mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant. 2005;20:1693–701. [PubMed]
38. Jindal K, Chan CT, Deziel C, et al. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol. 2006;17:S1–27. [PubMed]
39. Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int. 1992;41:1286–91. [PubMed]
40. Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (drip). A randomized, controlled trial. Hypertension. 2009;53:500–7. [PMC free article] [PubMed]
41. Rahman M, Fu P, Sehgal AR, Smith MC. Interdialytic weight gain, compliance with dialysis regimen, and age are independent predictors of blood pressure in hemodialysis patients. Am J Kidney Dis. 2000;35:257–65. [PubMed]
42. Khosla UM, Johnson RJ. Hypertension in the hemodialysis patient and the “Lag phenomenon”: Insights into pathophysiology and clinical management. Am J Kidney Dis. 2004;43:739–51. [PubMed]
43. Flanigan MJ, Khairullah QT, Lim VS. Dialysate sodium delivery can alter chronic blood pressure management. Am J Kidney Dis. 1997;29:383–91. [PubMed]
44. Santos SF, Peixoto AJ. Revisiting the dialysate sodium prescription as a tool for better blood pressure and interdialytic weight gain management in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:522–30. [PubMed]
45. Chan CT, Jain V, Picton P, Pierratos A, Floras JS. Nocturnal hemodialysis increases arterial baroreflex sensitivity and compliance and normalizes blood pressure of hypertensive patients with end-stage renal disease. Kidney Int. 2005;68:338–44. [PubMed]
46. Chan CT, Shen XS, Picton P, Floras J. Nocturnal home hemodialysis improves baroreflex effectiveness index of end-stage renal disease patients. J Hypertens. 2008;26:1795–800. [PubMed]
47. Beecroft JM, Duffin J, Pierratos A, Chan CT, McFarlane P, Hanly PJ. Decreased chemosensitivity and improvement of sleep apnea by nocturnal hemodialysis. Sleep Med. 2009;10:47–54. [PubMed]
48. Ruzicka M, Burns KD, Culleton B, Tobe SW. Treatment of hypertension in patients with nondiabetic chronic kidney disease. Can J Cardiol. 2007;23:595–601. [PMC free article] [PubMed]
49. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis. 1997;30:659–64. [PubMed]
50. Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006;70:1318–24. [PubMed]
51. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation. 1994;90:2786–96. [PubMed]
52. Verresen L, Fink E, Lemke HD, Vanrenterghem Y. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney Int. 1994;45:1497–1503. [PubMed]
53. Suzuki H, Kanno Y, Sugahara S, et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: An open-label randomized controlled trial. Am J Kidney Dis. 2008;52:501–6. [PubMed]
54. London GM, Marchais SJ, Guerin AP, et al. Salt and water retention and calcium blockade in uremia. Circulation. 1990;82:105–13. [PubMed]
55. Griffith TF, Chua BS, Allen AS, Klassen PS, Reddan DN, Szczech LA. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 2003;42:1260–9. [PubMed]
56. Tepel M, Hopfenmueller W, Scholze A, et al. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant. 2008;23:3605–12. [PubMed]
57. Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41:1438–44. [PubMed]
58. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346:580–90. [PubMed]
59. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000;57:307–13. [PubMed]
60. Kasiske BL. Epidemiology of cardiovascular disease after renal transplantation. Transplantation. 2001;72:S5–8. [PubMed]
61. Midtvedt K, Neumayer HH. Management strategies for posttransplant hypertension. Transplantation. 2000;70:S64–9. [PubMed]
62. Textor SC, Canzanello VJ, Taler SJ, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc. 1994;69:1182–93. [PubMed]
63. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol. 2000;(11 Suppl 15):S1–86. [PubMed]
64. Sanders CE, Jr, Curtis JJ. Role of hypertension in chronic renal allograft dysfunction. Kidney Int Suppl. 1995;52:S43–7. [PubMed]
65. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: The concept of accelerated senescence. J Am Soc Nephrol. 1999;10:167–81. [PubMed]
66. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int. 1998;53:217–22. [PubMed]
67. Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA. 2000;283:633–8. [PubMed]
68. Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis. 2004;43:1071–81. [PubMed]
69. Cosio FG, Pelletier RP, Pesavento TE, et al. Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients. Kidney Int. 2001;59:1158–64. [PubMed]
70. Strandgaard S, Hansen U. Hypertension in renal allograft recipients may be conveyed by cadaveric kidneys from donors with subarachnoid haemorrhage. Br Med J (Clin Res Ed) 1986;292:1041–4. [PMC free article] [PubMed]
71. Ponticelli C, Montagnino G, Aroldi A, Angelini C, Braga M, Tarantino A. Hypertension after renal transplantation. Am J Kidney Dis. 1993;21:73–8. [PubMed]
72. Bartholomeusz B, Hardy KJ, Nelson AS, Phillips PA. Modulation of nitric oxide improves cyclosporin A-induced hypertension in rats and primates. J Hum Hypertens. 1998;12:839–44. [PubMed]
73. Farge D, Julien J. Effects of transplantation on the renin angiotensin system (RAS) J Hum Hypertens. 1998;12:827–32. [PubMed]
74. Zhang R, Leslie B, Boudreaux JP, Frey D, Reisin E. Hypertension after kidney transplantation: Impact, pathogenesis and therapy. Am J Med Sci. 2003;325:202–8. [PubMed]
75. Bruno S, Remuzzi G, Ruggenenti P. Transplant renal artery stenosis. J Am Soc Nephrol. 2004;15:134–41. [PubMed]
76. Perez Fontan M, Rodriguez-Carmona A, Garcia Falcon T, Fernandez Rivera C, Valdes F. Early immunologic and nonimmunologic predictors of arterial hypertension after renal transplantation. Am J Kidney Dis. 1999;33:21–8. [PubMed]
77. Singer J, Gritsch HA, Rosenthal JT. The transplant operation and its surgical complications. In: Danovitch GM, editor. Handbook of Kidney Transplantation. 4th edn. Philadelphia: Lippincott Williams and Wilkins; 2005. pp. 193–211.
78. Prasad GV, Nash MM, Zaltzman JS. A prospective study of the physician effect on blood pressure in renal-transplant recipients. Nephrol Dial Transplant. 2003;18:996–1000. [PubMed]
79. Jacobi J, Rockstroh J, John S, et al. Prospective analysis of the value of 24-hour ambulatory blood pressure on renal function after kidney transplantation. Transplantation. 2000;70:819–27. [PubMed]
80. Matteucci MC, Giordano U, Calzolari A, Turchetta A, Santilli A, Rizzoni G. Left ventricular hypertrophy, treadmill tests, and 24-hour blood pressure in pediatric transplant patients. Kidney Int. 1999;56:1566–70. [PubMed]
81. Kooman JP, Christiaans MH, Boots JM, van Der Sande FM, Leunissen KM, van Hooff JP. A comparison between office and ambulatory blood pressure measurements in renal transplant patients with chronic transplant nephropathy. Am J Kidney Dis. 2001;37:1170–6. [PubMed]
82. Haydar AA, Covic A, Jayawardene S, et al. Insights from ambulatory blood pressure monitoring: Diagnosis of hypertension and diurnal blood pressure in renal transplant recipients. Transplantation. 2004;77:849–53. [PubMed]
83. Stenehjem AE, Gudmundsdottir H, Os I. Office blood pressure measurements overestimate blood pressure control in renal transplant patients. Blood Press Monit. 2006;11:125–33. [PubMed]
84. Ramesh Prasad GV, Huang M, Nash MM, Zaltzman JS. The role of dietary cations in the blood pressure of renal transplant recipients. Clin Transplant. 2006;20:37–42. [PubMed]
85. EBPG Expert Group on Renal Transplantation European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.2. Cardiovascular risks. Arterial hypertension. Nephrol Dial Transplant. 2002;17(Suppl 4):25–6. [PubMed]
86. Opelz G, Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant. 2005;5:2725–31. [PubMed]
87. Ferreira SR, Moises VA, Tavares A, Pacheco-Silva A. Cardiovascular effects of successful renal transplantation: A 1-year sequential study of left ventricular morphology and function, and 24-hour blood pressure profile. Transplantation. 2002;74:1580–7. [PubMed]
88. Prasad GV, Ahmed A, Nash MM, Zaltzman JS. Blood pressure reduction with HMG-coA reductase inhibitors in renal transplant recipients. Kidney Int. 2003;63:360–4. [PubMed]
89. Hohage H, Bruckner D, Arlt M, Buchholz B, Zidek W, Spieker C. Influence of cyclosporine A and FK506 on 24 h blood pressure monitoring in kidney transplant recipients. Clin Nephrol. 1996;45:342–4. [PubMed]
90. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7:1506–14. [PubMed]
91. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation. 2001;72:777–86. [PubMed]
92. Kreis H, Oberbauer R, Campistol JM, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol. 2004;15:809–17. [PubMed]
93. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562–75. [PubMed]
94. Pelletier RP, Akin B, Ferguson RM. Prospective, randomized trial of steroid withdrawal in kidney recipients treated with mycophenolate mofetil and cyclosporine. Clin Transplant. 2006;20:10–8. [PubMed]
95. Midtvedt K, Hartmann A, Foss A, et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation. 2001;72:1787–92. [PubMed]
96. Kothari J, Nash M, Zaltzman J, Ramesh Prasad GV. Diltiazem use in tacrolimus-treated renal transplant recipients. J Clin Pharm Ther. 2004;29:425–30. [PubMed]
97. Martinez-Castelao A, Hueso M, Sanz V, Rejas J, Alsina J, Grinyo JM. Treatment of hypertension after renal transplantation: Long-term efficacy of verapamil, enalapril, and doxazosin. Kidney Int Suppl. 1998;68:S130–4. [PubMed]
98. Stigant CE, Cohen J, Vivera M, Zaltzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy. Am J Kidney Dis. 2000;35:58–63. [PubMed]
99. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol. 2006;17:889–99. [PubMed]
100. Opelz G, Zeier M, Laux G, Morath C, Dohler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: A collaborative transplant study report. J Am Soc Nephrol. 2006;17:3257–62. [PubMed]
101. Knoll GA, Cantarovitch M, Cole E, et al. The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation – study design. Nephrol Dial Transplant. 2008;23:354–8. [PubMed]
102. Geddes CC, McManus SK, Koteeswaran S, Baxter GM. Long-term outcome of transplant renal artery stenosis managed conservatively or by radiological intervention. Clin Transplant. 2008;22:572–8. [PubMed]
103. Hricik DE. Long-term management issues in kidney transplantation. In: Norman DJ, Turka LA, editors. Primer on Transplantation. 2nd edn. Mt Laurel: American Society of Transplantation; 2001. pp. 474–9.
104. Fluck S, Preston R, McKane W, et al. Intra-arterial stenting for recurrent transplant renal artery stenosis. Transplant Proc. 2001;33:1245–6. [PubMed]
105. Sierre SD, Raynaud AC, Carreres T, Sapoval MR, Beyssen BM, Gaux JC. Treatment of recurrent transplant renal artery stenosis with metallic stents. J Vasc Interv Radiol. 1998;9:639–44. [PubMed]
106. Fervenza FC, Lafayette RA, Alfrey EJ, Petersen J. Renal artery stenosis in kidney transplants. Am J Kidney Dis. 1998;31:142–8. [PubMed]
107. Curtis JJ, Luke RG, Diethelm AG, Whelchel JD, Jones P. Benefits of removal of native kidneys in hypertension after renal transplantation. Lancet. 1985;2:739–42. [PubMed]
108. Fricke L, Doehn C, Steinhoff J, Sack K, Jocham D, Fornara P. Treatment of posttransplant hypertension by laparoscopic bilateral nephrectomy? Transplantation. 1998;65:1182–7. [PubMed]

Articles from The Canadian Journal of Cardiology are provided here courtesy of Pulsus Group